Arrowhead's much-anticipated cholesterol drug hits the mark again in phase 2 hyperlipidemia trial

Arrowhead Pharmaceuticals’ hotly anticipated cholesterol disorder drug lowered key lipoproteins that increase the risk of cardiovascular disease in a phase 2 trial, supporting a late-stage program.

The company presented results from the midstage MUIR study of plozasiran at the 92nd European Atherosclerosis Society Congress and published them in The New England Journal of Medicine on Tuesday.